Cost-Effectiveness of Routine and Campaign Use of Typhoid Vi-Conjugate Vaccine in Gavi-Eligible Countries: A Modelling Study
This article, published in The Lancet Infectious Diseases, reports the results of a modelling study to evaluate the cost-effectiveness of typhoid conjugate vaccine in low- and middle-income countries with varying typhoid burdens. The study modelled four strategies: no vaccination, routine immunization at 9 months, and routine immunization at 9 months with catch-up campaigns to either age 5 years or 15 years of age. The results indicate that vaccination is likely to be cost-effective in countries with high typhoid incidence, high cost of typhoid treatment, and/or high death rates from typhoid. Furthermore, results indicate that it is always cost-effective to include a catch-up campaign when introducing routine typhoid vaccination.
Author: Bilcke J, Antillon M, Pieters Z, et al.
» Visit web page (English)
(Located at www.thelancet.com)
Citation: Bilcke J, Antillon M, Pieters Z, et al. Cost-Effectiveness of Routine and Campaign Use of Typhoid Vi-Conjugate Vaccine in Gavi-Eligible Countries: A Modelling Study. The Lancet Infectious Diseases. 2019;19(7):728-739.
Resource types: Peer-reviewed journal